Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Biotech

Neuralink

Neuralink raises $650M Series D at $8B valuation

Fremont, CAMay 20, 20251 min read
Total Raised
$650M
Valuation
$8B
Latest Round
Series D
Employees
400+

Neuralink: Series D Funding Round

Neuralink has successfully raised $650M in Series D funding, reaching a valuation of $8B.

Company Overview

Brain-computer interface technology

Funding Details

The Series D round was led by Founders Fund, with participation from DFJ Growth.

Company Information

  • Headquarters: Fremont, CA
  • Founded: 2016
  • Employees: 400+
  • Category: Biotech

Investment

Neuralink plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Founders Fund: Verified investor in Series D
  • DFJ Growth: Verified investor in Series D

Company Info

Headquarters
Fremont, CA
Founded
2016
Team Size
400+
Last Round
$650M(May 2025)

Investors (2)

F
Founders FundLead
Lead Investor
Verified investor in Series D
D
DFJ Growth
Investor
Verified investor in Series D

Topics

verified(3079)real-funding(3079)neuralinkbiotechseries-dfremont

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min readβ€’$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min readβ€’$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min readβ€’$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free